It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ABBV’s FA Score shows that 4 FA rating(s) are green whileJNJ’s FA Score has 4 green FA rating(s), and NVS’s FA Score reflects 4 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ABBV’s TA Score shows that 5 TA indicator(s) are bullish while JNJ’s TA Score has 4 bullish TA indicator(s), and NVS’s TA Score reflects 6 bullish TA indicator(s).
ABBV (@Pharmaceuticals: Major) experienced а +5.37% price change this week, while JNJ (@Pharmaceuticals: Major) price change was -1.28% , and NVS (@Pharmaceuticals: Major) price fluctuated +2.33% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +1.88%. For the same industry, the average monthly price growth was +3.62%, and the average quarterly price growth was +4.98%.
ABBV is expected to report earnings on Jul 31, 2026.
JNJ is expected to report earnings on Oct 20, 2026.
NVS is expected to report earnings on Oct 27, 2026.
The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
| ABBV | JNJ | NVS | |
| Capitalization | 452B | 603B | 295B |
| EBITDA | 16.9B | 33.7B | 22.4B |
| Gain YTD | 14.734 | 22.441 | 14.978 |
| P/E Ratio | 125.54 | 29.07 | 22.04 |
| Revenue | 62.8B | 96.4B | 56.6B |
| Total Cash | N/A | 22.1B | 6.98B |
| Total Debt | 72.9B | 55B | 47B |
ABBV | JNJ | NVS | ||
|---|---|---|---|---|
OUTLOOK RATING 1..100 | 85 | 77 | 68 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 62 Fair valued | 14 Undervalued | 10 Undervalued | |
PROFIT vs RISK RATING 1..100 | 5 | 6 | 6 | |
SMR RATING 1..100 | 1 | 36 | 28 | |
PRICE GROWTH RATING 1..100 | 8 | 12 | 48 | |
P/E GROWTH RATING 1..100 | 17 | 14 | 25 | |
SEASONALITY SCORE 1..100 | 30 | 75 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
NVS's Valuation (10) in the Pharmaceuticals Major industry is in the same range as JNJ (14) and is somewhat better than the same rating for ABBV (62). This means that NVS's stock grew similarly to JNJ’s and somewhat faster than ABBV’s over the last 12 months.
ABBV's Profit vs Risk Rating (5) in the Pharmaceuticals Major industry is in the same range as NVS (6) and is in the same range as JNJ (6). This means that ABBV's stock grew similarly to NVS’s and similarly to JNJ’s over the last 12 months.
ABBV's SMR Rating (1) in the Pharmaceuticals Major industry is in the same range as NVS (28) and is somewhat better than the same rating for JNJ (36). This means that ABBV's stock grew similarly to NVS’s and somewhat faster than JNJ’s over the last 12 months.
ABBV's Price Growth Rating (8) in the Pharmaceuticals Major industry is in the same range as JNJ (12) and is somewhat better than the same rating for NVS (48). This means that ABBV's stock grew similarly to JNJ’s and somewhat faster than NVS’s over the last 12 months.
JNJ's P/E Growth Rating (14) in the Pharmaceuticals Major industry is in the same range as ABBV (17) and is in the same range as NVS (25). This means that JNJ's stock grew similarly to ABBV’s and similarly to NVS’s over the last 12 months.
| ABBV | JNJ | NVS | |
|---|---|---|---|
| RSI ODDS (%) | 1 day ago 37% | 1 day ago 44% | N/A |
| Stochastic ODDS (%) | 1 day ago 56% | 1 day ago 46% | 1 day ago 55% |
| Momentum ODDS (%) | 1 day ago 62% | 1 day ago 54% | 1 day ago 45% |
| MACD ODDS (%) | 1 day ago 43% | 1 day ago 44% | 1 day ago 40% |
| TrendWeek ODDS (%) | 1 day ago 62% | 1 day ago 42% | 1 day ago 53% |
| TrendMonth ODDS (%) | 1 day ago 64% | 1 day ago 47% | 1 day ago 50% |
| Advances ODDS (%) | 6 days ago 59% | 6 days ago 45% | 6 days ago 52% |
| Declines ODDS (%) | 9 days ago 48% | 8 days ago 42% | 9 days ago 46% |
| BollingerBands ODDS (%) | 1 day ago 38% | 1 day ago 45% | 1 day ago 59% |
| Aroon ODDS (%) | 1 day ago 66% | 1 day ago 44% | 1 day ago 47% |
A.I.dvisor indicates that over the last year, ABBV has been loosely correlated with BMY. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if ABBV jumps, then BMY could also see price increases.
| Ticker / NAME | Correlation To ABBV | 1D Price Change % | ||
|---|---|---|---|---|
| ABBV | 100% | +1.07% | ||
| BMY - ABBV | 53% Loosely correlated | +1.28% | ||
| NVS - ABBV | 49% Loosely correlated | +2.88% | ||
| AMGN - ABBV | 46% Loosely correlated | +0.57% | ||
| MRK - ABBV | 45% Loosely correlated | +1.50% | ||
| JNJ - ABBV | 42% Loosely correlated | +0.72% | ||
More | ||||
A.I.dvisor indicates that over the last year, NVS has been closely correlated with GSK. These tickers have moved in lockstep 66% of the time. This A.I.-generated data suggests there is a high statistical probability that if NVS jumps, then GSK could also see price increases.